Clinical trials: Psoriatic Arthritis (PsA)
Psoriasis (PsO), PsA (Psoriatic Arthritis)
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved…
- Conditions
- Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- EMERGE (NCT07255781)
- Testing
- Guselkumab Prefilled Syringe [Tremfya]
- Sponsor
- University of California, San Diego
Rheumatoid Arthritis, Psoriatic Arthritis
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
This study will establish a comparison in follow-up care of 100 patients between Health Care Practitioners, more specifically the rheumatologist and a trained nurse.
- Trial name
- APRAN (NCT02556034)
- Testing
- Disease evaluation.
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Isabelle Fortin
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Psoriatic Arthritis
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis
- Trial name
- CHERISH (NCT04163016)
- Testing
- Pharmacokinetics of certolizumab pegol
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).
- Trial name
- Complete-PsA (NCT01559038)
- Where
- 41 sites in Canada
- Volunteers
- 483 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
PsA Secukinumab XCT Structural Progression Study
Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability.
- Trial name
- NCT03623867
- Testing
- Secukinumab
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Psoriatic Arthritis (PsA)
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body.
- Trial name
- NCT07111494
- Testing
- GLP-1 agonists, Nutrition Counseling
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical College of Wisconsin
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Psoriasis (PsO), Psoriatic Arthritis (PsA)
A Clinical Trial of Antiplatelets in Psoriasis
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more…
- Trial name
- NCT07744191
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROCID-DCH (NCT03456206)
- Testing
- Intake of red and processed meat and fibres, Lifestyle factors independently or combined
- Where
- Denmark
- Volunteers
- 57,053 people
- Sponsor
- University of Southern Denmark
Psoriatic Arthritis
Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis…
- Trial name
- SAGE-PsA (NCT05954364)
- Where
- Canada
- Volunteers
- 540 people
- Sponsor
- Women's College Hospital
Psoriatic Arthritis
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study
Objectives: To identify a candidate set of biomarkers specific to AxPsA. Overview: Clinical and imaging characterization of PsA patients will be combined with extensive molecular assessment of both liquid and tissue compartments…
- Trial name
- MONOLITH (NCT05925842)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
PsA Patients Fulfilling CASPAR Criteria in Remission
Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission
Comparison of the proportion of Psoriatic arthritis patients in ultrasound remission (i.e. no power Doppler synovitis, tenosynovitis, dactylitis, enthesitis, PD=0) depending on whether patient and physician's global assessment of…
- Trial name
- PARURE (NCT03396679)
- Testing
- Ultrasound examination
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Psoriatic Arthritis (PsA)
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants
The purpose of this study is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a chronic inflammatory disorder.
- Trial name
- ALTEA (NCT03419143)
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in…
- Trial name
- PDUS (NCT02662985)
- Testing
- AIN457 (secukinumab)
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who…
- Trial name
- COMPOSITION (NCT07298265)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Psoriatic Arthritis
Diet Interventions in Psoriatic Arthritis
The purpose of this study is to learn whether changing diet impacts psoriatic arthritis (PsA).
- Trial name
- DIPSA (NCT04180904)
- Testing
- Diet 1, Diet 2
- Where
- 2 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- University of Pennsylvania
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT06671483
- Testing
- Zasocitinib, Active Comparator
- Where
- 188 sites in United States, Belgium and 18 more
- Volunteers
- 1,088 people
- Sponsor
- Takeda
Psoriatic Arthritis, Work Productivity
To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)
This post marketing observational study is designed to provide the initial data on work impairment of PsA patients in Turkey, as well as changes in work impairment, life quality and clinical response during treatment with…
- Trial name
- NCT02028169
- Volunteers
- 120 people
- Sponsor
- AbbVie